{"id":964949,"date":"2026-05-19T17:27:09","date_gmt":"2026-05-19T21:27:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/valion-bio-briefs-senior-department-of-war-and-barda-officials-in-joint-engagement-on-entolimod-for-acute-radiation-syndrome\/"},"modified":"2026-05-19T17:27:09","modified_gmt":"2026-05-19T21:27:09","slug":"valion-bio-briefs-senior-department-of-war-and-barda-officials-in-joint-engagement-on-entolimod-for-acute-radiation-syndrome","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/valion-bio-briefs-senior-department-of-war-and-barda-officials-in-joint-engagement-on-entolimod-for-acute-radiation-syndrome\/","title":{"rendered":"VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical Countermeasure<\/i>\n <\/p>\n

\n SAN ANTONIO<\/span>, May 19, 2026<\/span> \/PRNewswire\/ —\u00a0Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innate immunotherapeutics company, today announced that it presented Entolimod\u00a0for acute radiation syndrome (ARS) to senior officials from the U.S. Department of War and the Biomedical Advanced Research and Development Authority (BARDA) in a joint briefing held on May 14, 2026. The session was Valion Bio’s second engagement with senior Department of War officials, following the Company’s April 28, 2026, Pentagon briefing on Entolimod.<\/p>\n

\n

\n
\n \"VALION
\n <\/a>\n <\/p>\n<\/p><\/div>\n

We believe the cross-agency engagement reflects continued U.S. government interest in Entolimod\u00a0as a differentiated medical countermeasure for radiological threats. Agency discussion included a specific interest in an oral formulation of the Company’s lead candidate, which would offer operational advantages over injectable agents in mass-casualty scenarios and support broader field deployment for the warfighter. and national stockpile integration.<\/p>\n

“This second engagement, requested by the DoW, at senior levels of the Department of War, conducted jointly with BARDA, reflects the increasing interest of Entolimod\u00a0within the national radiological preparedness conversation,” said Michael K. Handley<\/b>, Chief Executive Officer of Valion Bio. “Cross-agency interest at this level signals that policymakers recognize the strategic importance of a differentiated, dual-tissue radiation countermeasure, and the specific focus on a potential oral formulation underscores the operational realities of field deployment and stockpile readiness that our platform is positioned to address.”<\/p>\n

Entolimod is a novel Toll-like receptor 5 (TLR5) agonist that activates NF-\u03baB signaling to stimulate bone marrow and protect gastrointestinal tissues following ionizing radiation exposure \u2014 a dual-tissue mechanism not available in currently stockpiled countermeasures. Unlike Neupogen\u00ae (filgrastim), Neulasta\u00ae (pegfilgrastim), and Leukine\u00ae (sargramostim), which target hematopoietic recovery alone, Entolimod\u00a0addresses the gastrointestinal damage that is often the limiting factor for survival at higher radiation doses. Valion Bio is working to advance both injectable and oral transmucosal formulations of Entolimod\u00a0to support a broad range of deployment scenarios.<\/p>\n

The May 14 briefing follows prior Valion Bio engagements with BARDA, the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Company’s selection for the Department of War’s Tech Watch program. To date, over $140 million has been invested in the Entolimod\u00a0program, including approximately $35.6 million in non-dilutive U.S. government funding. The compound has been evaluated in 42 non-human primate studies and administered to approximately 300 human subjects, demonstrating a well-characterized safety and efficacy profile.<\/p>\n

“The current geopolitical environment continues to elevate radiological preparedness on the national security agenda, and we are seeing that reflected in the depth and frequency of our engagement with U.S. government stakeholders,” Mr. Handley continued. “Our objective is straightforward: to ensure that Entolimod \u2014 and an oral formulation positioned for mass casualty and warfighter applications \u2014 is recognized and supported at the levels required to translate its differentiated profile into deployed national capability.”<\/p>\n

The Company has received FDA Fast Track and Orphan Drug designations for Entolimod\u00a0in acute radiation syndrome and is advancing the program toward a Biologics License Application under the FDA’s Animal Rule.<\/p>\n

\n Strategic and Competitive Positioning<\/b>\n <\/p>\n